Hepatology Research

Article	Citations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	195
Efficacy and Safety of Direct Oral Anticoagulants in Budd–Chiari Syndrome After Percutaneous Recanalization	64
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	63
Deceased Donation Disparities in East Asia—A Tale of Two Systems	49
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	47
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	44
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	38
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	38
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	37
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	35
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	35
Factors associated with portopulmonary hypertension	34
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	33
Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study	29
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	27
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	25
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	24
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	24
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	23
Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma	23
Acknowledgment	22
The change from NAFLD to MAFLD expands fatty liver information flow	22
Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation	22
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	21
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	21

Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption	20
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	20
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	19
	18
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	18
Issue Information	17
Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	17
Issue Information	17
Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	16
	16
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	16
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	16
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	16
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	16
Issue Information	16
Chronic liver disease questionnaire to manage patients with chronic liver diseases	15
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	15
Issue Information	15
	15
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	15
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	15
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis	14
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	13
Issue Information	13
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis	13
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	13
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	13
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study	13
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	13
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	12
Measurement of spleen length and two‐dimensional spleen index is comparable to spleen volumetry by computed tomography for predicting esophageal varices	12
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	12
Quantitative evaluation of tumor signal heterogeneity on gadoxetic acid‐enhanced magnetic resonance imaging as a predictor of postoperative survival and antitumor immunity in hepatocellular carcinoma	12
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	12
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	12
	11
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	11
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	11
Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma	11
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	11
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	11
	11
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	11
	11
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	11
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	11
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation	10
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	10
HCV Elimination Strategies for Maximum Effectiveness, Tailored to National and Regional Circumstances	10
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	10

Cost‐effectiveness of hepatitis E virus vaccination strategy	10
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	10
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	10
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	10
Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD	10
	9
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	9
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	9
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	9
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan	9
	9
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	9
The role of the nervous system in liver diseases	9
	9
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	8
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	8
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	8
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	8
Erratum	8
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	8
Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis	8
Issue Information	8
Issue Information	8
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	8
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	8
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	8
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	8
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	8
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	8
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	8
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	8
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	7
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	7
Issue Information	7
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	7
Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma	7
	7
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	7
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	7
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	7
Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept	7
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	7
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	7
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	7
Evaluating the liver function of patients with hepatocellular carcinoma	7
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	7
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	7
Metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?	7
	7
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	6
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	6
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	6
Advancing Gene Mutation Analysis Through Post‐Ablation Liver Tumor Biopsy Specimens	6
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	6
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
Tamoxifen‐Induced Liver Injury in Patients With Breast Cancer: Frequency, Risk Factors and Clinical Course	6
	6
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	6
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	6
Issue Information	6
Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	6
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	6
	6
Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma	6
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	6
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	6
Lipolysis‐Stimulated Lipoprotein Receptor Gene Variants as a Cause of Progressive Familial Intrahepatic Cholestasis: A Case Report	6
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	6
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	6
SOX9 Is a Key Factor for the Postnatal Maturation of the Intrahepatic Bile Duct Network	6
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	6
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	6
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	6
Issue Information	6
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	5
Acknowledgment	5
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	5
Acknowledgments	5
	5
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease	5

Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy	5
Issue Information	5
Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations	5
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	5
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	5
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade	5
Caution Regarding Short‐Term Increases in Ammonia Levels Following Splenic Artery Embolization	5
Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers	5
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	5
Issue Information	5
Acknowledgment	5
The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography	5
Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study	5
Clinical benefits of partial splenic embolization for cancer patients	5
Mac‐2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis	5
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	5
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study	5
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	5
Issue Information	5
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	5
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study	4
Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma	4
High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma	4
Cachexia is an independent predictor of mortality in patients with cirrhosis	4
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study	4
Issue Information	4
Defining advanced lymph node metastasis in intrahepatic cholangiocarcinoma: A multicenter study	4
Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug‐Induced Liver Injury	4
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical	4
Corrigendum	4
An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	4
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	4
Pathological significance of intranuclear structures in liver biopsy samples	4
Issue Information	4
Exosomal circCMTM3 promotes the pathogenesis of hepatocellular carcinoma via angiogenesis	4
Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey	4
Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy	4
	4
A classification model for resectability in hepatocellular carcinoma patients	4
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	4
Issue Information	4
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy	4
	4
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic k	4
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma	4
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in healt	4
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	3
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	3
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide seq	3
Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance	3
Issue Information	3
Liver imaging reporting and data with perfluorobutane microbubbles—Is there hope?	3
Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake	3
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma	3
Identification of reversed portal flow on 4DCT and of factors contributing to reversed portal flow in patients with liver cirrhosis and portosystemic shunt before interventional radiology procedures	3
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice	3
Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease	3
Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection	3
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	3
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients	3
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease	3
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	3
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study	3
Serum pro‐inflammatory cytokine interleukin‐6 level is predictive of further decompensation and mortality in liver cirrhosis	3
Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection	3
Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus	3
Real‐world trends in acute viral hepatitis in Japan: A nationwide questionnaire‐based survey	3
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	3
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study	3
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	3
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey	3
Issue Information	3
Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease	3
Obesity Decreases Liver‐Related Death in Patients With Cirrhosis: A Retrospective Propensity Score‐Matched Study	3
	3
	3
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab	3
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	3
Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease	2
Significance of malnutrition defined with Global Leadership Initiative on Malnutrition criteria in patients with hepatocellular carcinoma after hepatic resection	2
Clinical Evaluation of Initial Experiences With the Qualitative Dual Detection of Core Antigen and Antibodies Immunoassay for Hepatitis C Virus Screening Test	2
Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease	2
	2
Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan	2
Makuuchi's criteria for liver resection in the modern era of functional liver remnant volume evaluation	2
Pathological changes of a malignant liver tumor after systemic therapies	2
MET amplification as a potential therapeutic target against hepatocellular carcinoma	2
Genetic alteration of SLCO1B3 defines constitutional indocyanine green excretory defect in patients who underwent hepatectomy	2
Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs	2
	2
What we know and need to know about Fontan‐associated liver disease	2
Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease	2
Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth	2
Issue Information	2
	2